2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Intestinal Neoplasms
2
Colorectal Neoplasms
2
Papillomavirus Infections
1
Malaria
1
Lymphoma, Follicular
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Carcinoma, Hepatocellular
1
CIN 2/3
1
Breast Neoplasms
1
Interventions
Irinotecan
8
Bevacizumab
8
Fluorouracil
7
Leucovorin
6
Oxaliplatin
5
Capecitabine
4
Drug Therapy
3
Cetuximab
3
5,10-methylenetetrahydrofolic acid
3
Radiotherapy
2
Levoleucovorin
2
Folfox protocol
2
Colonoscopy
2
Bisacodyl
2
Aspirin
2
Artesunate
2
trametinib
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
nazartinib
1
napabucasin
1
lutetium Lu 177 dotatate
1
guadecitabine
1
encorafenib
1
copper dotatate CU-64
1
canakinumab
1
camrelizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Intestinal Neoplasms
×
Artesunate
×
Clear all
NCT07095309
2025-07-31
NeoART-M
Metanoic Health Ltd.
Phase 2
Not yet recruiting
120 enrolled
NCT02633098
2022-10-12
NeoART
St George's, University of London
Phase 2
Unknown
200 enrolled